Cargando…
Osilodrostat in Cushing’s disease: the management of its efficacy and the pitfalls of post-surgical results
SUMMARY: Osilodrostat is a novel, orally administered cortisol synthesis inhibitor, approved in 2020 by the European Medicines Agency (EMA) for the treatment of Cushing’s syndrome in adults. A significant amount of the studies currently available in the literature focus on treatment in patients with...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Bioscientifica Ltd
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716402/ https://www.ncbi.nlm.nih.gov/pubmed/36515363 http://dx.doi.org/10.1530/EDM-22-0311 |